Temporal Trends in Anti-Diabetes Drug Use in TRICARE Following Safety Warnings in 2007 About Rosiglitazone

Kate A. Stewart, Brenda M. Natzke, Thomas V. Williams, Elder Granger, S. Ward Casscells and Thomas W. Croghan

Mathematica Policy Research Reports from Mathematica Policy Research

Abstract: In 2007, highly publicized warnings suggested rosiglitazone, a drug used to treat type 2 diabetes, may be associated with an increased risk of heart attack and cardiovascular-related death.

Keywords: diabetes; TRICARE; thiazolidinediones; rosiglitazone; pioglitazone (search for similar items in EconPapers)
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www3.interscience.wiley.com/journal/122535639/abstract (text/html)
Our link check indicates that this URL is bad, the error code is: 403 Forbidden (http://www3.interscience.wiley.com/journal/122535639/abstract [301 Moved Permanently]--> https://www3.interscience.wiley.com/journal/122535639/abstract)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:mpr:mprres:4112dd90998d4f7b9d6f78533281a005

Access Statistics for this paper

More papers in Mathematica Policy Research Reports from Mathematica Policy Research Mathematica Policy Research P.O. Box 2393 Princeton, NJ 08543-2393 Attn: Communications. Contact information at EDIRC.
Bibliographic data for series maintained by Joanne Pfleiderer () and Cindy George ( this e-mail address is bad, please contact ).